Abivax stock advanced after a late Thursday regulatory development that removed a prominent source of uncertainty for the biotech. Shares rose 3.7% to trade at 2112.5 following the company's disclosure that it had successfully completed a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration regarding obefazimod, Abivax's lead therapy candidate for adults with moderately to severely active ulcerative colitis.
The FDA's feedback, as described by the company, confirmed full alignment on Abivax's planned NDA submission strategy as well as on the content and format of the regulatory dossier. Company officials characterized this outcome as clearing one of the most consequential procedural steps that must be navigated before a formal New Drug Application can be filed.
Chief Executive Officer Marc de Garidel commented on the meeting, stating that "achieving alignment with the FDA on our NDA submission strategy marks an important milestone as we prepare to submit Abivaxs first New Drug Application for obefazimod," and added that the result builds on the positive Phase 3 ABTECT program data announced earlier in the year.
Abivax reiterated its previously stated timetable to submit the NDA by the end of 2026. That deadline has been closely monitored by investors following a volatile period for the stock: a sharp sell-off in June driven by safety data concerns was followed by a partial recovery after updated trial results were released.
Analysts have generally remained constructive toward the company. Multiple firms are cited as carrying Buy or Overweight ratings, with price targets reportedly well above the current trading level, a factor that likely supports investor demand when regulatory clarity improves.
The broader market environment also provided a favorable backdrop for biotech and other risk-sensitive assets on the day in question. U.S. equity benchmarks posted solid gains, with the Nasdaq leading the advance at 1.4%. The CAC 40, France's main benchmark, traded in positive territory as well. Market commentary from the session noted there were no major disruptive macro releases or central bank announcements dominating trading, which contributed to a generally constructive tone across equities.
Taken together, the removal of the specific regulatory uncertainty represented by the pre-NDA meeting outcome, a constructive analyst community, and a supportive market backdrop encouraged investors to push Abivax shares higher. Intraday, the stock reached a session high of 2113.7 before settling near the current level, comfortably above the 2108.5 prior close.
Key points
- Abivax completed a pre-NDA meeting with the U.S. Food and Drug Administration for obefazimod, with the FDA confirming alignment on the NDA submission strategy and dossier format.
- The company reaffirmed its plan to submit the NDA by the end of 2026; this follows a period of volatility including a June sell-off over safety concerns and later recovery on updated trial results.
- Market conditions were broadly positive during the session, with the Nasdaq up 1.4% and the CAC 40 also trading higher, which supported appetite for biotech and other risk assets.
Risks and uncertainties
- Safety data concerns previously sparked a sharp share-price decline in June, underscoring that safety signals remain a material risk for clinical-stage biotechs and the healthcare sector.
- The companys stated timeline to file the NDA by the end of 2026 is an objective that remains subject to execution and further regulatory interaction.
- Market sentiment can shift; although the day saw supportive macro conditions with no major disruptive releases, changes in broader equity markets could affect biotech valuations and investor appetite.
The pre-NDA meeting outcome represents a notable procedural advance for Abivax but does not itself constitute an approval or a completed regulatory filing. Investors and market participants will likely continue to monitor forthcoming regulatory steps, company updates on dossier preparation, and any additional clinical or safety data that could influence the path to a formal NDA submission.